Abstract
Copyright: © 2014 Kerr T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Impressive gains continue to be made in the global fight against HIV disease. Notably, a new and growing body of observational and experimental evidence has revealed the powerful role that antiretroviral therapy can play in reducing not only morbidity and mortality at the individual level, but also HIV transmission at the population level [1,2]. This has led to renewed calls for the aggressive scale-up of HIV treatment, calls that have been supported by an array of cost effectiveness studies and prompted slogans referring to a potential “AIDS-free generation”. In addition, several studies demonstrated the potential efficacy of pre-exposure prophylaxis (PrEP) among HIVnegative individuals at risk, although fears regarding low adherence and implementation challenges resulted in a low uptake of this intervention. In 2013, the US Centers for Disease Control and Prevention released new evidence from the Bangkok Tenofovir Study suggesting that the benefits of PrEP interventions could likely be extended to people who inject drugs [3]. This trial built upon the results of previous studies reporting on potential benefits of PrEP for men who have sex with men and heterosexually active women and men [4-6].
Highlights
Transgender women are individuals born as males but who later assume a feminine gender expression or identity [7]
Of 0.4% in the general population [21]. In response to this and other related challenges, the national government instituted the new law that establishes a framework based on equity and human rights, and that acknowledges the right to self-defined gender identity
Significant progress has recently been made in the fight against HIV/AIDS, there is much work to be done
Summary
Transgender women are individuals born as males but who later assume a feminine gender expression or identity [7]. *Corresponding author: Thomas Kerr, Director, Urban Health Research Initiative, BC Centre for Excellence in HIV/AIDS, 608 - 1081 Burrard Street, Vancouver BC V6Z 1Y6, Canada, Tel: 604-806-9116; Fax: 604-806-9044; E-mail: uhri-tk@cfenet.ubc.ca
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
